iRhythm Technologies Earnings Call Highlights Profitable Surge

Irhythm Technologies ((IRTC)) has held its Q4 earnings call. Read on for the main highlights of the call.

iRhythm Technologies’ latest earnings call struck an upbeat tone, underscoring another quarter of volume‑driven revenue growth, expanding margins and landmark profitability and cash‑flow milestones. Management balanced this confidence with a candid discussion of regulatory delays, elevated spending and reimbursement uncertainty, but framed these as timing issues rather than structural threats to the growth story.

Strong Revenue Growth

iRhythm reported Q4 2025 revenue of $208.9 million, up 27.1% year over year, and full‑year revenue of $747.1 million, up 26.2%. This marked the company’s fifth consecutive quarter of revenue growth above 20%, highlighting sustained demand for its cardiac monitoring solutions despite a tougher healthcare and reimbursement backdrop.

Profitability and Cash Flow Milestones

The company delivered its first positive quarterly net income in history, posting Q4 net income of $5.6 million, or $0.17 per diluted share. Adjusted EBITDA reached $68.9 million for 2025, with margins of 9.2% for the year and 16.4% in Q4, while free cash flow of $34.5 million and a $583.8 million cash balance underline growing financial flexibility.

Margin Expansion

Gross margin improved to 70.9% in Q4 and 70.6% for the full year, reflecting gains of 90 and 170 basis points respectively versus last year. Adjusted EBITDA margins expanded by more than 1,000 basis points in 2025, with Q4 at 16.4%, signaling that scale and operational discipline are increasingly flowing through to profitability.

Market Leadership in Long‑Term Continuous Monitoring

Management estimates iRhythm holds roughly 72% share in long‑term continuous cardiac monitoring, a segment growing in the high teens annually. This leading position is supported by over 135 scientific publications, reinforcing the clinical credibility that underpins physician adoption and payer support for the Zio platform.

Zio AT Momentum and MCT Platform Positioning

Zio AT, the company’s near‑real‑time monitoring product, grew units at more than twice the company average and is said to have expanded more than 50% year over year, giving iRhythm an estimated 15% MCT share. A next‑generation MCT offering with 21‑day wear, enhanced form factor and upgraded algorithms is under FDA review, with commercial launch now expected in the first half of 2027.

Commercial Expansion and EHR Integration

More than one‑third of iRhythm’s volume now originates in primary care, with the company serving about 40,000 primary care physicians, highlighting the shift of cardiac diagnostics beyond cardiology. Over half of total volume flows through fully integrated EHR accounts and 75 of the top 100 customers are integrated, while home enrollment has reached around 23% of U.S. volume.

Data and AI Capabilities

The company continues to leverage a vast data asset of nearly 3 billion hours of curated ECG recordings from around 13 million patients. Early pilots in predictive AI, including work with Lucem Health, reportedly achieved more than 85% accuracy in pre‑identifying patients with clinically meaningful arrhythmias, pointing to future decision‑support and workflow opportunities.

International and Adjacent Market Progress

International operations in the U.K., select European markets and Japan remain small but are scaling, with the U.K. delivering its largest quarter of volume to date. iRhythm is also piloting sleep‑related offerings aimed at the roughly 40 million U.S. sleep apnea patients, and sees long‑term upside from markets that collectively conduct about 3 million ambulatory cardiac tests annually, where its share is currently below 1%.

Next‑Gen MCT Timing and FDA Questions

The company pushed the launch of its next‑generation MCT platform into the first half of 2027 following FDA questions and a required move to a new mobile gateway for cybersecurity reasons. While management remains confident in the product, the delay introduces timing risk around when meaningful incremental MCT revenue will materialize.

Full‑Year Net Loss and Rising Operating Expenses

Despite a profitable fourth quarter, iRhythm reported a full‑year 2025 net loss of $44.6 million, or $1.39 per diluted share, as it continues to invest heavily in growth and remediation. Operating expenses rose 11.8% year over year to $584.7 million, with Q4 opex at $145.8 million versus $119.2 million a year earlier, tempering near‑term earnings leverage.

Regulatory and Reimbursement Uncertainty

Management highlighted industry scrutiny around chart‑derived diagnoses and shifting reimbursement policies, which could alter payment dynamics across digital monitoring. The company’s guidance does not assume upside from potential changes to chart‑scraping policies, and while Medicare rates improved for Zio Monitor, they were slightly lower for AT, creating a mixed reimbursement backdrop.

One‑Time Collections True‑Up and Pricing Conservatism

Q4 benefited from a one‑time collections reserve true‑up worth a low single‑digit million‑dollar boost to realized pricing. However, management is taking a cautious view and did not bake this into 2026 assumptions, guiding to overall pricing that is roughly flat versus 2025 despite some Medicare rate movements.

Limited Near‑Term Contribution from Innovative and International Channels

The innovative channel, which includes newer partnerships and models, remains a low single‑digit percentage of revenue despite showing an improved exit rate. International markets also remain early, with less than 1% share across target countries, so management framed both as long‑dated growth drivers with more meaningful contributions likely beyond 2027.

Remaining FDA Remediation and Implementation Costs

Ongoing remediation efforts and FDA‑related work continue to weigh on expenses, limiting how fast margins can expand in the near term. Management emphasized that these costs should moderate over time, but for now they represent an additional drag that investors must factor into near‑term profitability expectations.

MCT and Gateway Technology Tradeoffs

To address cybersecurity concerns, iRhythm opted to move to a locked mobile gateway where it initially provides the device, rather than relying on patients’ smartphones. This choice adds development and deployment complexity and may slow the rollout of broader smartphone‑based features, but is intended to create a more secure and controlled platform foundation.

Forward‑Looking Guidance and Profitability Roadmap

For 2026, iRhythm guided to revenue of $870 million to $880 million, implying 16% to 18% growth and a moderation from 2025’s 26.2% pace, with Q1 revenue of $193 million to $195 million. The company expects flat pricing but 80 to 100 basis points of gross margin improvement, adjusted EBITDA margins of 11.5% to 12.5%, stronger free cash flow skewed to the back half and remains focused on a $1 billion revenue goal in 2027 as international, Zio AT and innovative channels grow faster than the core.

iRhythm’s call painted the picture of a company transitioning from high‑growth disruptor to scaled, cash‑generative leader in ambulatory cardiac monitoring. While regulatory complexity, MCT delays and elevated expenses present near‑term challenges, management’s conservative guidance, strong balance sheet and expanding margins suggest the fundamental growth story remains intact for long‑term investors.